Citations

Clear

635 citation(s) found for "Holmes, D R".

Agentic AI-Generated vs. Clinician-Authored Hospital Course Narratives for Cardiology Hospitalizations: A Blinded Physician Evaluation
Lee, Eunjung , Harmon, David , Holmes, Jason , Allman, Alexandra E. , Saey, Stephanie , Schlesinger, Reid P , Félix, Iuri Ferreira , Friedman, Paul A , Attia, Zachi I.

Mayo Clinic

Circulation: Population Health and Outcomes | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circoutcomes.126.014472 | PMID 42993583 Get It

Background: Discharge summaries are essential for safe transitions of care, but writing the hospital course narrative is time intensive. Large language models can generate plausible clinical narratives, yet prior approaches often rely on static inputs and remain vulnerable to omissions and factual inconsistencies. Methods: We developed an electronic health record (EHR)-integrated agentic artificial intelligence (AI) system that uses Gemini 2.5 Pro and Model Context Protocol tools to retrieve clinical notes, diagnostic reports, diagnoses, medications, and appointments on demand. In this retrospective, blinded, paired study, 50 inpatient cardiology encounters were randomly selected from admissions July 13 to 27, 2024, at Mayo Clinic, Rochester, Minnesota. Five physicians rated AI-generated and clinician-authored hospital course narratives for each encounter (250 ratings) on 0-to-10 scales for overall quality, clarity, completeness, accuracy, and readability and indicated a preference. The primary outcome was the paired difference in overall quality (linear mixed-effects model with crossed random intercepts for encounter and reviewer). Secondary domains were analyzed similarly with Bonferroni adjustment, and preference with a crossed random-effects logistic model. Results: Clinician-authored narratives were preferred in 132 ratings (52.8%) and AI-generated narratives in 118 (47.2%) (odds ratio for clinician-authored preference, 1.12; 95% CI, 0.71 to 1.78). Overall quality did not differ significantly (mean, 7.27 AI-generated versus 7.42 clinician-authored; difference, -0.15; 95% CI, -0.86 to 0.56; p=0.627). AI-generated narratives were rated higher for clarity (0.36; 95% CI, 0.07 to 0.65) and readability (0.72; 95% CI, 0.20 to 1.24) but lower for completeness (-0.84; 95% CI, -1.36 to -0.32) and accuracy (-0.35; 95% CI, -0.66 to -0.05). After Bonferroni correction, only lower completeness remained significant (adjusted p=0.012). Conclusions: Hospital course narratives generated by the EHR-integrated agentic AI system did not differ significantly from clinician-authored narratives in physician-rated overall quality or preference. Lower completeness supports continued clinician review before use in the medical record.
Metaproteomic analysis of human sonicate fluid highlights neutrophil extracellular trap formation associated with periprosthetic joint infection
Garcia, Elijah , O'Connor, Kathleen , Koscianski, Christina A , Alvarez Otero, Judith , O'Donnell, Keara, Larson, Nicholas B , Pandey, Akhilesh , Holmes, David R , Patel, Robin

Mayo Clinic

Microbiology Spectrum | October 13, 2026 | Volume: 14 | Issue: 11 | Pages: No page available

10.1128/spectrum.00665-26 | PMID 42867249 Get It

ABSTRACT Periprosthetic joint infection (PJI) is a devastating complication of total joint arthroplasty that can be challenging to diagnose and treat. Neutrophils are a prominent feature in PJI, with neutrophil extracellular traps (NETs) known to be present; little is known, however, about the physiology of PJI-associated NETs. Here, the proteomes of PJI and non-infectious arthroplasty failure (NIAF), analyzed using liquid chromatography tandem mass-spectrometry (LC-MS/MS) and proximity extension assay (PEA)-based profiling of fluids derived from sonication of arthroplasty components removed from patients who had undergone revision arthroplasty, were compared, with a focus on NET formation. In addition, in vitro effects of synovial fluid components on Staphylococcus aureus- induced NET formation were characterized. LC-MS/MS (PJI n = 85, NIAF n = 26) and PEA (PJI n = 95, NIAF n = 39) showed NET formation and neutrophil degranulation to be associated with PJI, with the complement cascade and platelet activation pathways identified as potential contributors. In vitro studies showed delayed NET formation in artificial synovial fluid compared to standard cell culture media conventionally used to evaluate NETs. Together, these results demonstrate the presence of NETs in PJI, identify potential pathways involved in PJI-associated NETosis, and point to an influence of synovial components on NET formation during PJI. IMPORTANCE Periprosthetic joint infection (PJI) is a major complication of joint replacement, placing a significant burden on patients and the healthcare system. Our research reveals that neutrophils and their antimicrobial “traps” are dominant features of the immune response at the infection joint site. Importantly, we found that the unique environment of the joint delays the formation of these traps, potentially contributing to the pathogenesis of PJI. By establishing a new experimental platform tailored for the infected joint, this work provides a foundational platform for probing these mechanisms and supports the development of improved diagnostic and therapeutic strategies.
Standardized endpoint definitions for trials of transcatheter left atrial appendage closure: a consensus from the Left Atrial Appendage Academic Research Consortium
Garot, Philippe , Mehran, Roxana , Backer, Ole De , Freeman, James V. , Wunderlich, Nina, Hibbert, Benjamin , Tzikas, Apostolos , Nair, Devi, Berti, Sergio, Saw, Jacqueline , Freixa, Xavier, Doshi, Shephal K. , Cruz-Gonzalez, I, Coylewright, Megan, Aminian, Adel, Sanchis, L, Ruff, Christian T, Landmesser, Ulf, Lakkireddy, Dhanunjaya , Alasnag, Mirvat, Yamamoto, Masanori , Iwamoto, Shin, Shiba, Takeshi , Jin, Y Z, Jagadeesan, Vikrant, Krucoff, Mitchell W., Nielsen-Kudsk, Jens Erik, Gibson, C Michael, Gurol, Edip Mahmut, Cutlip, Don E, Leon, Martin B, Holmes, David R. , Morice, M C, Alkhouli, Mohamad, De Backer, Ole , Räber, Lorenz , Lakkireddy, Dhanunjaya , Ellis, Christopher , Yamamoto, Masanori , Schmidt, Boris , Hildick-Smith, David , Oliva, Angelo , Spitzer, Ernest , Holmes, David R , Mehran, Roxana , Hibbert, Benjamin , Freeman, James V , Tzikas, Apostolos , Freixa, Xavier , Cruz‐González, Ignacio , Coylewright, Megan , Aminian, Adel , Price, Matthew J. , Räber, Lorenz , Yao, Xiaoxi , Sanchís, Laura , Ruff, Christian Thomas , Landmesser, Ulf , Ellis, Christopher R. , Alasnag, Mirvat , Ferro, Enrico Giuseppe , Shiba, Takeshi, Jin, Yu, Reddy, Vivek Y. , Spitzer, Ernest , Nielsen‐Kudsk, Jens Erik , Gibson, C. Michael , Gurol, M. Edip , Cutlip, Donald E. , Leon, Martin B. , Alkhouli, Mohamad

Mayo Clinic

European Heart Journal | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurheartj/ehag482 | PMID 42425446 Get It

Abstract Since its introduction in 2002, left atrial appendage closure (LAAC) has rapidly expanded as an alternative to anticoagulation in patients with atrial fibrillation at high risk of stroke. Harmonized processes for data collection, analysis, and reporting in LAAC trials are essential to enhance research quality and improve clinical practice. The Left Atrial Appendage Academic Research Consortium (LAARC) initiative is an independent collaboration of academic research organizations, cardiology and neurology experts, clinical trialists, and regulatory authorities from the USA, Europe, and Asia. The consortium engaged clinical experts, regulators—including the US Food and Drug Administration (FDA), European Notified Bodies, and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)—and industry leaders to define standardized study elements and endpoints for LAAC trials. Key considerations included alignment with prior Academic Research Consortium initiatives, procedural and mechanistic insights, and clinical relevance. Consensus definitions were proposed for mortality, stroke, bleeding, and device performance, along with composite endpoints for safety and effectiveness. The proposed LAARC consensus definitions aim to standardize endpoint reporting, improve comparability across studies, and support regulatory and clinical trial applications for this evolving therapy through broad dissemination in the peer-reviewed literature.
Proprioceptive Stimuli as a Trigger for Leucine-Rich Glioma-Inactivated-1 (LGI1) IgG Associated Autoimmune Seizures, a Case Report
Gupta, Ashutosh , Holmes, Miles D., Dubey, Divyanshu, Omidi, Shirin Jamal, Goyal, Megan, Sriwastava, Shitiz, Gupta, Rajesh , Gupta, Ashutosh , Gupta, Rajesh Kumar , Dubey, Divyanshu , Goyal, Megan, Sriwastava, Shitiz

Mayo Clinic

The Neurohospitalist | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/19418744261463745 | PMID 42368480 Get It

Leucine-rich glioma-inactivated-1 (LGI1) IgG-associated autoimmune encephalitis typically presents with faciobrachial dystonic seizures, hyponatremia, and temporal lobe MRI abnormalities. However, the clinical spectrum of LGI1 IgG-associated AE extends beyond these classical features, with reports of diverse seizure semiologies and atypical presentations challenging traditional diagnostic paradigms. This study reports a male in his late 60s presenting with recurrent episodes of right foot cramping and electric shock-like pain, progressing to generalized tonic-clonic seizures. Initial workup suggested chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but LGI1 IgG antibodies were subsequently detected. Despite treatment with intravenous immunoglobulin (IVIG), the seizures persisted. This case highlights the heterogeneity in LGI1 encephalitis presentations. The patient’s proprioceptive-induced reflex seizures represent a rare manifestation of the disease. Treatment with rituximab, a B-cell depleting therapy, resulted in significant improvement, suggesting its potential effectiveness in LGI1 encephalitis with a resistant seizure course. The case also emphasizes the intricate interplay between the mesial temporal lobe, basal ganglia, and frontal regions in LGI1 encephalitis pathophysiology.
The Target ALS Global Natural History Study: Cross-platform proteomics to accelerate biofluid biomarker and drug target discovery in amyotrophic lateral sclerosis
Yasui, Daisuke , Weatherill, Daniel, Dugom, Laura, Weiner, Sophia , Tran, Huy, Oskarsson, Björn, Nagle, Kyra, Miller, Timothy, Gutierrez, Gilbert, Ravits, John, Hoover, Benjamin, Harms, Matthew, Shneider, Neil, Neylon, Lizzi, Dailey, Whitney, Ladha, Shafeeq, Holmes, Cassandra, Lee, Joseph , Streicher, Nicholas, Nayar, Shakti, Harris, Brent T. , Raisinghani, Manish, Zetterberg, Henrik, Gobom, Johan, Easton, Amy, Bowser, R., Gopalakrishnan, Lathika , Ravits, John , Harms, Matthew B. , Shneider, Neil A. , Ladha, Shafeeq , Streicher, Nicholas, Nayar, Shakti, Zetterberg, Henrik , Gobom, Johan , Easton, Amy E. , Bowser, Robert , Ly, Cindy V.

Mayo Clinic

No container title available | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.13.26355379 | PMID 42396333 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal, rapidly progressive neurodegenerative disease of motor neurons for which therapeutics are limited. Improved biomarkers are imperative to improve patient care and therapeutic development. Here, we employed 35-plex isobaric tandem mass tag labeling based on isobutyl-proline reporter group (TMTpro) to perform unbiased proteomic analysis of cerebrospinal fluid (CSF) and plasma from control (n= 28, n= 31) and sporadic ALS (sALS) (n= 39, n= 41), from the Target ALS Global Natural History Study (TALS GNHS). We identified 2,875 proteins in CSF and 1,118 proteins in plasma and identified known and novel differentially expressed proteins (DEPs) between controls and sALS, some of which were orthogonally validated using immunoassay. Comparison of TMTpro-MS and Olink proximity extension assay proteomics revealed common and non-overlapping differentially expressed proteins illustrating strengths unique to each platform. This initial cross-sectional proteomic study of biofluids from the TALS GNHS, with unrestricted availability of study results to the research community, highlights the potential of this resource as a potent platform for ALS biomarker discovery.
Artificial Intelligence Models for Classifying Wrist Ligament Injuries Using Synthetically-Generated Joint Proximity Maps from Finite Element Models
Chen, Hsuan-Yu, Camp, Jon, Thoreson, Andrew R. , Leng, Shuai , Holmes, David R. , Kakar, Sanjeev , An, Kai‐Nan , Zhao, Kristin D. , Andreassen, Thor E. , Yu Chen, Hsuan, Trentadue, Taylor P , Thoreson, Andrew R , Leng, Shuai , Holmes, David R , Kakar, Sanjeev , An, Kai-Nan , Trentadue, Taylor P , Andreassen, Thor E , Camp, Jon J. , Trentadue, Taylor P.

Mayo Clinic

No container title available | June 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.17.733030 | PMID 42367846 Get It

Abstract Background/Purpose Diagnosing wrist ligament injuries is challenging; early detection and treatment are important to prevent osteoarthritis progression. Interosseous proximity maps, a proxy measure for joint space, can be generated from volumetric imaging data and may provide important information about wrist health. Artificial intelligence (AI) could enhance accuracy of noninvasive diagnosis based on imaging-derived metrics. This work demonstrates feasibility of AI training using synthetic proximity map data generated from finite element models (FEMs). Methods Personalized wrist FEMs for two asymptomatic participants were created from four-dimensional computed tomography-derived anatomic and kinematic data. Monte Carlo sampling varied 22 ligament material properties and simulated 7,500 unique injury scenarios generating 9,000,000 labeled red, green, and blue (RGB) images of interosseous proximity vector fields from FEM-derived motions. Images were associated with 17 descriptive metrics, including gross wrist angles and bone surface pairs, and used to develop mixed-input convolutional neural networks (CNNs). Model performance was evaluated for identifying specific ligament injuries. Results Average area under receiver operating characteristic curve (AUROC) for CNNs was 0.757 across all injury types and kinematics. In a subset with clinically-relevant functional angles, the average AUROC was 0.824. Best-performing individual ligament AUROCs ranged from 0.807 to 0.999. Sensitivities and specificities exceeded 0.99 for some ligament injury simulations under specific wrist angles and bone surface pairs. Conclusion This study demonstrates the feasibility of using synthetic data from FEMs to train AI models for classifying wrist ligament injuries. Proximity-based RGB images may be a relevant biomarker of ligamentous injury.
SenoQuant: One-stop AI software for senescence marker analysis and prediction
Lagnado, Anthony B. , Li, Yukang , Nwakama, Chibuzo C., Franco, Ana Catarina , Han, Yeaeun , Martini, Hélène , Victorelli, Stella, Hruby, Adam , Gomez, Lilian Salez, 우승화, Wyles, Saranya, Khalfaoui, Latifa, Costa, Daniela G. , Khosla, Sundeep, Prakash, YS, Camp, Jon, Holmes, David, Nwakama, Chibuzo, Jurk, Diana , Victorelli, Stella , Lee, Gung , Saul, Dominik , Gomez, Lilian Sales , Wyles, Saranya P. , Khalfaoui, Latifa, Sokka, Miiko , Khosla, Sundeep , Neretti, Nicola , Prakash, YS, Camp, Jon J. , Passos, João F.

Mayo Clinic

No container title available | June 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.18.733222 Get It

Abstract Senescent cells accumulate with age and contribute to tissue dysfunction, yet their identification in tissues is challenging due to low abundance, heterogeneous phenotypes, and the lack of specific markers. Senescence-associated features span multiple subcellular compartments, including nuclear DNA damage foci, cytosolic protein changes, and perinuclear alterations, each requiring tailored detection strategies. To overcome these challenges, we developed SenoQuant ( https://github.com/HaamsRee/senoquant ), a versatile software designed for comprehensive, accurate, and unbiased spatial quantification and prediction of senescence markers across diverse tissue contexts. Utilizing AI models, SenoQuant enables precise nuclear and cytoplasmic segmentation and detection of senescence markers across low- and high-plex imaging modalities, applicable to cultured cells and tissue sections from mice and humans. The platform also supports custom AI models; for example, we built SenCeption, a proof-of-concept predictor of single-cell p21 status from DAPI-stained nuclei in human skin. Available as a free napari plugin, SenoQuant is widely accessible to researchers. By providing a unified approach to senescence analysis and prediction, SenoQuant opens new opportunities for exploring the complex biology of senescence and its impacts on aging and disease.
Research through Evaluation for Large Language Model in Patient-Clinician Communications
Holmes, Jason, Hobson, Jared, Bennett, Alexandra, McKone, Elizabeth L. , Ebner, Daniel, Shiraishi, Satomi, Patel, Samir H. , Yu, Nathan Y. , Hallemeier, Chris L., Ball, Brooke E., Waddle, Mark, Liu, Wei, Hao, Yuexing , Holmes, Jason , Routman, David M. , Kalantari, Saleh , Ghassemi, Marzyeh

Mayo Clinic

No container title available | June 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9735115/v1 | PMID 42370275 Get It

Abstract Large Language Models (LLMs) demonstrate strong capabilities in healthcare applications. However, recruiting human evaluators to assess usability and effectiveness becomes challenging in the large-scale LLM-generated outcomes. Existing metrics are often outdated for evaluating LLM-based healthcare technologies. This paper proposes a Research through Evaluation (RtE) approach that can refine metrics and improve assessments of LLM-generated outputs. We deploy RtE in a retrospective comparative study of prostate cancer patient inquiries, comparing responses from human clinical care teams with those generated by a GPT-4-based in-basket bot. Through three rounds of co-evaluations with clinical professionals and an LLM-as-graders study with four LLMs, the RtE method shows that starting with small, iterative evaluations helps human graders adjust metrics to suit their daily practices better. Additionally, in the LLM-as-graders study, LLMs exhibit similar behavior, preferring the in-basket bot's responses over the clinical care team. Our methodology and findings demonstrate that the RtE method can enhance the transparency and robustness of evaluation metrics for LLM-generated content, with the potential to generalize to evaluations in other clinical practices.
CAMPERR: A multicenter, prospective, observational study to evaluate a cfDNA-based genome-wide methylation enrichment assay for multicancer early detection (MCED), identification of molecular residual disease, and relapse prognostication.
Idos, Gregory, Holmes, Faith L., Boardman, Lisa A., Mazzone, Peter J. , Nabavizadeh, Nima , Lammers, Phil, Ahluwalia, M., Padmanabhan, Arvinda, Burkeen, Christopher Grant, Nash, Charles H., Clyburn-Ipock, Virginia L., Okeke, Ifeoma Roseline, Byrnes, Abigail B., Silvestri, Gerard A., Anderson, Michelle H., Landers, Kaytlin, Provance, Jeremy , Sosa, Eduardo V., Allen, Brian, Rini, Brian I., Idos, Gregory , Boardman, Lisa A., Lammers, Philip E. , Ahluwalia, Manmeet S. , Burkeen, Christopher G. , Silvestri, Gerard A. , Allen, Brian, Rini, Brian I.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps10628 Get It

TPS10628 Background: Despite advances in cancer treatment, a lack of established population-level cancer screening strategies for early detection across cancer types contributes to cancer-related mortality. Emerging MCED liquid biopsy tests represent a screening approach with potential to enable detection of multiple malignancies at earlier stages in the disease process. We previously showed that an initial classifier based on a genome-wide methylome enrichment platform detected 12 cancer types, including early-stage, low-shedding tumors (Park et al. AACR 2023. Abs 1030). However, clinical performance of the platform has not been evaluated prospectively. Thus, the CAMPERR study (NCT05366881) was designed to train and validate a cell-free methylated DNA immunoprecipitation and high throughput sequencing (cfMeDIP-seq)-based test for detection and differentiation of 20 pre-selected cancer types, representing 93% of annual cancer incidence and 88% of annual cancer deaths. Longitudinal follow-up for a subset of participants with lung cancer will enable training and validation for MRD-based recurrence prognostication. Methods: This case-control study is enrolling participants with 20 different pre-specified cancer types (n=2400) and those without known cancer (n=3900). Eligible participants are ≥40 years of age and not receiving treatment for cancer at the time of enrollment or taking any demethylating/hypomethylating agents. Cases include individuals with newly diagnosed (≤120 days), untreated cancer or recurrence of a cancer originally diagnosed >5 years ago. Cancers of interest are stage I-IV bladder, brain, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. Participants with stage I-III lung cancer will have clinical follow-up and blood draws after completion of first-line treatment, every 3 mo for the first year thereafter, and every 6 mo for an additional 2 years. Eligible control participants have not been diagnosed with invasive cancer in the last 5 years and will have clinical follow-up ≥12 mo from enrollment to evaluate cancer status. Liquid biopsy results will not be returned to clinicians or participants. The primary objective is cancer detection. Secondary objectives include detection of specific cancer types, identification of the tissue of origin, and prognostication of clinical outcomes (eg, recurrence-free survival, overall survival). CAMPERR is currently enrolling at 15 sites. As of December 3, 2025, 2108 of 2400 cancer cases have been enrolled, including prostate (n=225), lung (n=216), colorectal (n=211), breast (n=193), and pancreatic (n=192); controls are fully enrolled. Clinical trial information: NCT05366881 .
In vitro susceptibility of Stenotrophomonas maltophilia and other carbapenem non-susceptible Gram-negative rods in the Pacific Northwest to cefiderocol and aztreonam-avibactam
Bryan, Andrew , Shields-Pruiett, Megan, Berger, Heather, Fang, Ferric C. , Penewit, Kelsi , Waalkes, Adam , Holmes, Elizabeth A. , Salipante, Stephen J. , Werth, Brian J. , Bryan, Andrew

Mayo Clinic

JAC-Antimicrobial Resistance | May 28, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/jacamr/dlag105 | PMID 42267315 Get It

Abstract Objectives Carbapenem resistance is a growing public health crisis with regional variability in incidence. We characterized the susceptibility of carbapenem-resistant Gram-negative rods (CR-GNRs) from the Pacific Northwest to five reserve beta-lactam agents including cefiderocol and aztreonam-avibactam. Methods A panel of 162 CR-GNRs from unique patients were tested against cefiderocol, aztreonam-avibactam, ceftazidime-avibactam, meropenem-vaborbactam and ceftolozane-tazobactam, with a subset of isolates derived from patients with bacteraemia (n = 55). Whole-genome sequencing (WGS) was performed on representative Stenotrophomonas maltophilia isolates displaying a range of cefiderocol MICs (n = 9). Results Among all isolates, the MIC50 and MIC90 to cefiderocol was 0.25 and 4 mg/L, respectively, compared with 4 and >64 mg/L for aztreonam-avibactam. Overall, 98.3% of S. maltophilia (n = 60), 91.2% of Enterobacterales (n = 34) and 88.5% of Pseudomonas aeruginosa (n = 26) isolates were susceptible to cefiderocol, while 78.6% of other non-fermenters had MICs ≤4 mg/L. Aztreonam-avibactam and cefiderocol exhibited similar activity against Enterobacterales and S. maltophilia, but aztreonam-avibactam was less active against other organisms. WGS of S. maltophilia isolates with elevated cefiderocol MICs identified disruptive mutations in PBP-encoding genes (mrcB/PBP1b and pbpC/PBP1c) that were not observed in highly susceptible isolates. The bacteraemia cohort had many comorbidities and a 29% 30 day all-cause mortality. In this cohort, cefiderocol demonstrated the highest in vitro activity as extrapolated from MICs, followed by ceftazidime-avibactam, aztreonam-avibactam, meropenem-vaborbactam and ceftolozane-tazobactam, respectively. Conclusions Cefiderocol exhibited the greatest in vitro activity against various CR-GNRs species in a Pacific Northwest population enriched for severely ill patients. Susceptibility to other agents was more variable among tested organisms.